

NANODx

Currently doing business as BioDirection, Inc.



**Point of Care
Covid-19 Viral
Antigen Test Solution**

POINT-OF-CARE — CAPABILITY —

BENEFITS

- Portable
- Easy-to-Use
- Safe
- Objective
- Fast
- Affordable

PLATFORM DEVICE

- Multiple biomarkers
- Patented algorithm
- Multiple diseases

DIGITAL ASSAY TEST

- Finger stick of whole blood
- Nanosensor technology
- Measures targeted biomarkers
- Results in seconds
- No need for reagents
- Rapid application development

HANDHELD ANALYZER AND CARTRIDGE

- Graphical user interface
- Real-time sample analysis
- Single-use disposable

IOT CLOUD CONNECTIVITY

- Software/firmware upgrades
- Hospital systems integration
- Utilization tracking
- Data aggregation
- Learning algorithms
- QC compliance
- Service assistance

LOCATION FLEXIBILITY

- Hospital
- Ambulance
- First responder
- Urgent care
- Doctor's office
- Elder care
- Patient use




NanoDx C-19 adds simplicity and safety with choice of saliva or finger stick testing

Challenges with Throat Swab

- Deep throat or nose with firm access required
- Standard in PCR tests for Covid-19
- Potential for false negative due to inadequate sampling¹
 - Undermines confidence in tests
- More PPE required

Benefits of Finger Stick or Saliva Sample

- Easy to administer
- Less room for operator error (layperson)
- Some pain associated²
- Less PPE required



1. Harlan Krumholz, MD, Yale University
2. American Diabetes Association


NanoDx COVID-19 Viral Antigen test: From sample draw to result in under 5 minutes



Overview of Technology

- Utilizes nano-wire technology to simplify test to measure electrical current vs. reagent complexity of an ELISA and incubation associated with PCR
- Test done anywhere sample draw occurs
- Removes wait time of transport to lab and return of result. Patient receives result at time of draw
- Utilizes either whole blood finger stick or saliva
- Test result in 2 minutes, total TAT under 5 minutes
- Delivers “Positive” or “Negative” result verified via EUA guidance for Antigen test*
- COVID-19 application requires no changes to platform design (analyzer nor cassette)
- NanoDx platform technology FDA designated as a breakthrough technology and being fast tracked for approval of the Traumatic Brain Injury use

720 tests and notifications per system/day



*final performance accuracy to be verified upon completion of EUA test protocol, this is not an FDA cleared test

NanoDx COVID-19 addresses the key testing need: Speed and High Sensitivity



NanoDx Technology Advantages


Key Points on Current Tests Available

1. Predominance of current high sensitivity tests are based on PCR and are performed in lab setting
 - 2-hour transit time with 2-hour test time
2. Current high-speed POC tests on the market are low sensitivity

NanoDx addresses the need for speed and accuracy

- NanoDx POC sample to result in under 5 minutes, test time in under 2 minutes.
- All at the POC and with high sensitivity without sample preparation nor amplification - simple POC

Performance vs. Competition



*final performance accuracy to be verified upon completion of EUA test protocol, this is not an FDA cleared test



NANO Dxx

POC Covid-19 Viral Antigen Test

- Built on FDA breakthrough designated technology
- Easy to Use any where it is needed
- Blood or Saliva sample reduces discomfort, transmission and improves accuracy
- Each system delivers up to 720 completed and patient notified results a day in under 5 minutes per test

True Point of Care allows the world to get back to business



TSA Screen

Work Screen




School Screen

- Infections will continue, we have just slowed the growth
- Pre-screening may be a reality for large groups to gather
- Back to Work / School Screening
- TSA screening for viruses
- Stadium screening
- Company event screening
- 4 hour or 10-minute tests are not effective

Sports Screen



The Near Future: NanoDx leverages IoT to assist towards a return to normalcy; gain access to work, school, events with proof











- Scan ID / Image for Authentication
- Ties into IoT
- Ties into Web Portal for CDC
- Easy to track Employee Status

Steve (left) tested positive and has proof on his phone and is exempt from work
Stephanie (right) tested negative and can gain access to the conference

IoT & Web Portal System future option tracks data



- 
Clients
- 
Users
- 
Systems
- 
Tests
- 
QC
- 
Reports
- 
Settings



BioDIRECTION

Clients Users Systems Tests QC Reports Settings

BioDIRECTION

Clients Users Systems Tests QC Reports Settings

Name	Model	Location	Serial #	IP Address	Date Installed	Date Expires	Status	Notices
Tbit System	123456	Boston, MA	123456	123456	3-24-20	3-24-23	Active	None ▶
Tbit System	123456	Boston, MA	133456	123456	3-24-20	3-24-23	Active	None ▶
Tbit System	123456	Boston, MA	143456	124456	3-24-20	3-24-23	Active	None ▶


Selected System Status: Active

Name: Tbit System	Serial #: 123456
Model: 123456	IP Address: 123456
Location: Boston, MA	Date Installed: 3-24-20
Department: Emergency	Date Expires: 3-24-23
Software: 123456	Firmware: 123456
Notices: 0	Audit Trail: 0
Notes:	



SAVE

Innovative NanoDx COVID-19 Cassette Manufacturing Process in place

Scale up of validated 8-step cartridge manufacturing process does not require a change to our current technology nor materials for scale up. Scale up is solely reliant on installation of additional manufacturing equipment




NanoDx: A Company History of Innovation



NanoDX C-19 System: 100% designed & assembled in the USA



5 USA Regions: Sales Executives focused on providing solutions to customers



An Experienced Leadership Team



Sharad Joshi **President & CEO**

Global entrepreneurial medical devices CEO with 34 years of experience and a strong track record of driving rapid global growth and laying the strategic foundations for sustained success.

James Wylie **Executive Chairman**

Proven business leader with 35 years of executive management experience in emerging and global businesses in both public and private sector companies.

Sergey Dryga **Chief Scientific Officer**

Experienced product development leader with expertise in nanotechnology, molecular biology, protein engineering, system integration, and electrical and software engineering.

Tony Tremaglio **Vice President of Marketing**

Entrepreneurial medical device marketing leader with a successful 27-year track record across all stages of global market and product development in emerging to Fortune 500 companies.

Mike Sampson **Vice President North America**

Accomplished global commercial leader with a successful 26-year track record in strategic sales, business development and marketing management within the medical device and diagnostics point-of-care IVD industry.

Marco Witteveen **Vice President Europe**

Accomplished commercial leader with a successful 27-year track record in strategic sales & marketing management within the medical device & diagnostics point-of-care IVD industry worldwide.